Diamyd Medical AB (publ) (DMYD-B) - Total Liabilities
Based on the latest financial reports, Diamyd Medical AB (publ) (DMYD-B) has total liabilities worth Skr147.23 Million SEK (≈ $15.84 Million USD) as of May 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check DMYD-B financial resilience to evaluate the company's liquid asset resilience ratio.
Diamyd Medical AB (publ) - Total Liabilities Trend (2010–2025)
This chart illustrates how Diamyd Medical AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Diamyd Medical AB (publ).
Diamyd Medical AB (publ) Competitors by Total Liabilities
The table below lists competitors of Diamyd Medical AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kier Group PLC
LSE:KIE
|
UK | GBX2.63 Billion |
|
Amj Land Holdings Limited
NSE:AMJLAND
|
India | Rs352.18 Million |
|
FAWER Automotive Parts Ltd Co
SHE:200030
|
China | HK$9.40 Billion |
|
Cordoba Minerals Corp
V:CDB
|
Canada | CA$7.61 Million |
|
Eden Innovations Ltd
AU:EDE
|
Australia | AU$19.59 Million |
|
Carlin Gold Corporation
V:CGD
|
Canada | CA$44.37K |
|
Ateliers Mecaniques D’Indonesie Tbk PT
JK:AMIN
|
Indonesia | Rp114.00 Billion |
|
FINEDIGITAL Inc
KQ:038950
|
Korea | ₩11.17 Billion |
Liability Composition Analysis (2010–2025)
This chart breaks down Diamyd Medical AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Diamyd Medical AB (publ) balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.57 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Diamyd Medical AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Diamyd Medical AB (publ) (2010–2025)
The table below shows the annual total liabilities of Diamyd Medical AB (publ) from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-08-31 | Skr72.64 Million ≈ $7.82 Million |
+2.14% |
| 2024-08-31 | Skr71.12 Million ≈ $7.65 Million |
+95.32% |
| 2023-08-31 | Skr36.41 Million ≈ $3.92 Million |
+64.42% |
| 2022-08-31 | Skr22.14 Million ≈ $2.38 Million |
+81.83% |
| 2021-08-31 | Skr12.18 Million ≈ $1.31 Million |
-29.50% |
| 2020-08-31 | Skr17.28 Million ≈ $1.86 Million |
+51.24% |
| 2019-08-31 | Skr11.42 Million ≈ $1.23 Million |
-4.56% |
| 2018-08-31 | Skr11.97 Million ≈ $1.29 Million |
-0.10% |
| 2017-08-31 | Skr11.98 Million ≈ $1.29 Million |
+40.70% |
| 2016-08-31 | Skr8.52 Million ≈ $916.35K |
+19.58% |
| 2015-08-31 | Skr7.12 Million ≈ $766.33K |
+3.80% |
| 2014-08-31 | Skr6.86 Million ≈ $738.25K |
-8.83% |
| 2013-08-31 | Skr7.52 Million ≈ $809.70K |
-38.13% |
| 2012-08-31 | Skr12.16 Million ≈ $1.31 Million |
-79.26% |
| 2011-08-31 | Skr58.63 Million ≈ $6.31 Million |
-76.96% |
| 2010-08-31 | Skr254.41 Million ≈ $27.38 Million |
-- |
About Diamyd Medical AB (publ)
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with ty… Read more